A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Condition studied

Advanced Cancer

Investigational medicinal product(s)

Every trial of Pembrolizumab across our registers →

Eligibility

Primary endpoint

Part A1: First cycle dose-limiting toxicities., Part A1: AEs as characterized by type, frequency, severity (as graded by NCI CTCAE v6.0), timing, seriousness and relationship to study intervention., Part A1: Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v6.0), and timing., Part A2: AEs as characterized by type, frequency, severity (as graded by NCI CTCAE v6.0), timing, seriousness, and relationship to study intervention, Part A2:Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v6.0), and timing, Part A2: Preliminary antitumor activity: ORR by CT/MRI using RECIST 1.1 criteria per investigator assessment